BIOSYNEX (ALBIO.PA) Fundamental Analysis & Valuation

EPA:ALBIO • FR0011005933

Current stock price

0.784 EUR
-0.01 (-1.01%)
Last:

This ALBIO.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ALBIO.PA Profitability Analysis

1.1 Basic Checks

  • ALBIO had negative earnings in the past year.
  • ALBIO had a negative operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: ALBIO reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: ALBIO reported negative operating cash flow in multiple years.
ALBIO.PA Yearly Net Income VS EBIT VS OCF VS FCFALBIO.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

1.2 Ratios

  • ALBIO's Return On Assets of -47.50% is on the low side compared to the rest of the industry. ALBIO is outperformed by 84.48% of its industry peers.
  • Looking at the Return On Equity, with a value of -160.22%, ALBIO is doing worse than 82.76% of the companies in the same industry.
Industry RankSector Rank
ROA -47.5%
ROE -160.22%
ROIC N/A
ROA(3y)-10.54%
ROA(5y)6.39%
ROE(3y)-24.67%
ROE(5y)7.07%
ROIC(3y)N/A
ROIC(5y)N/A
ALBIO.PA Yearly ROA, ROE, ROICALBIO.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

1.3 Margins

  • With a Gross Margin value of 58.82%, ALBIO perfoms like the industry average, outperforming 56.90% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ALBIO has remained more or less at the same level.
  • ALBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.7%
GM growth 5Y-0.09%
ALBIO.PA Yearly Profit, Operating, Gross MarginsALBIO.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. ALBIO.PA Health Analysis

2.1 Basic Checks

  • ALBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ALBIO remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, ALBIO has more shares outstanding
  • ALBIO has a worse debt/assets ratio than last year.
ALBIO.PA Yearly Shares OutstandingALBIO.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
ALBIO.PA Yearly Total Debt VS Total AssetsALBIO.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • ALBIO has an Altman-Z score of -0.72. This is a bad value and indicates that ALBIO is not financially healthy and even has some risk of bankruptcy.
  • ALBIO's Altman-Z score of -0.72 is on the low side compared to the rest of the industry. ALBIO is outperformed by 81.03% of its industry peers.
  • A Debt/Equity ratio of 0.31 indicates that ALBIO is not too dependend on debt financing.
  • ALBIO's Debt to Equity ratio of 0.31 is in line compared to the rest of the industry. ALBIO outperforms 55.17% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z -0.72
ROIC/WACCN/A
WACC5.79%
ALBIO.PA Yearly LT Debt VS Equity VS FCFALBIO.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • ALBIO has a Current Ratio of 0.78. This is a bad value and indicates that ALBIO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.78, ALBIO is doing worse than 87.93% of the companies in the same industry.
  • ALBIO has a Quick Ratio of 0.78. This is a bad value and indicates that ALBIO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ALBIO has a Quick ratio of 0.45. This is amonst the worse of the industry: ALBIO underperforms 86.21% of its industry peers.
Industry RankSector Rank
Current Ratio 0.78
Quick Ratio 0.45
ALBIO.PA Yearly Current Assets VS Current LiabilitesALBIO.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. ALBIO.PA Growth Analysis

3.1 Past

  • ALBIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -41.10%.
  • ALBIO shows a decrease in Revenue. In the last year, the revenue decreased by -5.84%.
  • Measured over the past years, ALBIO shows a very strong growth in Revenue. The Revenue has been growing by 24.22% on average per year.
EPS 1Y (TTM)-41.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-56.71%
Revenue 1Y (TTM)-5.84%
Revenue growth 3Y-35.81%
Revenue growth 5Y24.22%
Sales Q2Q%-5.91%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y475%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year15.05%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALBIO.PA Yearly Revenue VS EstimatesALBIO.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
ALBIO.PA Yearly EPS VS EstimatesALBIO.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2019 2020 2021 2023 2024 2025 0 2 -2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

4

4. ALBIO.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • ALBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • The Price/Forward Earnings ratio is 1.65, which indicates a rather cheap valuation of ALBIO.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of ALBIO indicates a rather cheap valuation: ALBIO is cheaper than 100.00% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of ALBIO to the average of the S&P500 Index (21.99), we can say ALBIO is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 1.65
ALBIO.PA Price Earnings VS Forward Price EarningsALBIO.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALBIO.PA Per share dataALBIO.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

  • ALBIO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALBIO.PA Dividend Analysis

5.1 Amount

  • ALBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALBIO.PA Fundamentals: All Metrics, Ratios and Statistics

BIOSYNEX

EPA:ALBIO (4/28/2026, 7:00:00 PM)

0.784

-0.01 (-1.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-22
Earnings (Next)07-22
Inst Owners0.11%
Inst Owner ChangeN/A
Ins Owners5.7%
Ins Owner ChangeN/A
Market Cap14.70M
Revenue(TTM)97.95M
Net Income(TTM)-70.99M
Analysts86.67
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.65
P/S 0.15
P/FCF N/A
P/OCF N/A
P/B 0.33
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.31
EYN/A
EPS(NY)0.47
Fwd EY60.43%
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS5.22
BVpS2.36
TBVpS-1.52
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -47.5%
ROE -160.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58.82%
FCFM N/A
ROA(3y)-10.54%
ROA(5y)6.39%
ROE(3y)-24.67%
ROE(5y)7.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.7%
GM growth 5Y-0.09%
F-Score3
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.46%
Cap/Sales 4.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.78
Quick Ratio 0.45
Altman-Z -0.72
F-Score3
WACC5.79%
ROIC/WACCN/A
Cap/Depr(3y)143.09%
Cap/Depr(5y)301.13%
Cap/Sales(3y)20.88%
Cap/Sales(5y)14.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-41.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-56.71%
EPS Next Y475%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-5.84%
Revenue growth 3Y-35.81%
Revenue growth 5Y24.22%
Sales Q2Q%-5.91%
Revenue Next Year15.05%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-72.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2216.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y81.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.71%
OCF growth 3YN/A
OCF growth 5YN/A

BIOSYNEX / ALBIO.PA Fundamental Analysis FAQ

What is the fundamental rating for ALBIO stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALBIO.PA.


Can you provide the valuation status for BIOSYNEX?

ChartMill assigns a valuation rating of 4 / 10 to BIOSYNEX (ALBIO.PA). This can be considered as Fairly Valued.


What is the profitability of ALBIO stock?

BIOSYNEX (ALBIO.PA) has a profitability rating of 1 / 10.


Can you provide the financial health for ALBIO stock?

The financial health rating of BIOSYNEX (ALBIO.PA) is 1 / 10.


What is the expected EPS growth for BIOSYNEX (ALBIO.PA) stock?

The Earnings per Share (EPS) of BIOSYNEX (ALBIO.PA) is expected to grow by 475% in the next year.